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Background: Over 50% of patients with head and neck squamous cell carcinoma (HNSCC) present with
locoregionally advanced disease. Those at intermediate-to-high risk of recurrence after definitive therapy exhibit
advanced disease based on tumour size or lymph node involvement, non-oropharynx primary sites, human
papillomavirus (HPV)-negative oropharyngeal cancer, or HPV-positive oropharynx cancer with smoking history
(>10-pack-years). Non-surgical approaches include concurrent chemoradiotherapy, induction chemotherapy
followed by definitive radiotherapy or chemoradiotherapy, or radiotherapy alone. Following locoregional therapies
(including surgical salvage of residual cervical nodes), no standard intervention exists. Overexpression of epidermal
growth factor receptor (EGFR), an ErbB family member, is associated with poor prognosis in HNSCC. EGFR-targeted
cetuximab is the only targeted therapy that impacts overall survival and is approved for HNSCC in the USA or
Europe. However, resistance often occurs, and new approaches, such as targeting multiple ErbB family members,
may be required. Afatinib, an irreversible ErbB family blocker, demonstrated antiproliferative activity in preclinical
models and comparable clinical efficacy with cetuximab in a randomized phase II trial in recurrent or metastatic
HNSCC. LUX-Head & Neck 2, a phase III study, will assess adjuvant afatinib versus placebo following chemoradiotherapy
in primary unresected locoregionally advanced intermediate-to-high-risk HNSCC.
Methods/design: Patients with primary unresected locoregionally advanced HNSCC, in good clinical condition with
unfavourable risk of recurrence, and no evidence of disease after chemoradiotherapy will be randomized 2:1 to oral
once-daily afatinib (40 mg starting dose) or placebo. As HPV status will not be determined for eligibility, unfavourable
risk is defined as non-oropharynx primary site or oropharynx cancer in patients with a smoking history (>10 pack-years).
Treatment will continue for 18 months or until recurrence or unacceptable adverse events occur. The primary endpoint
measure is duration of disease-free survival; secondary endpoint measures are disease-free survival rate at 2 years,
overall survival, health-related quality of life and safety.
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Discussion: Given the unmet need in the adjuvant treatment of intermediate-to-high-risk HNSCC patients, it is
expected that LUX-Head & Neck 2 will provide new insights into treatment in this setting and might demonstrate the
ability of afatinib to significantly improve disease-free survival, compared with placebo.
Trial registration: ClinicalTrials.gov NCT01345669.
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The most common type of malignant tumour of the
head and neck is squamous cell carcinoma, with an esti-
mated global incidence of approximately 600,000 cases
per year [1]. Locoregionally advanced disease (stage III
to IVb) accounts for more than 50% of patients diag-
nosed with this cancer; 40% of patients present with
early-stage disease and 10% present with metastatic disease
at diagnosis [2]. Five-year overall survival rates vary in pa-
tients with locoregionally advanced disease. Overall survival
ranges from 10% to 75% depending on tumour stage,
the site of the primary tumour, human papillomavirus
(HPV) association and other known risk factors [3-7].
For oropharyngeal squamous cell carcinoma (OPSCC),
high-risk patients with locoregionally advanced disease
have been previously defined as patients with HPV-
negative tumours who either have a ≤10 pack-year smok-
ing history with T4 tumours (indicating invasion of the
primary tumour into adjacent tissues and structures, based
on the tumour-node-metastasis (TNM) Staging Classifica-
tion for Head and Neck Cancers) [8] or have a >10 pack-
year smoking history irrespective of primary tumour stage
[9,10]. Patients with HPV-positive OPSCC and a >10
pack-year smoking history also have a worse prognosis
and are defined as being at an intermediate risk of
death. This risk stratification model was confirmed in
a 2012 study by Broglie et al. [11]. Human papillomavi-
rus infection has emerged as an aetiological factor in
around 20 to 25% of head and neck squamous cell carcin-
oma (HNSCC) [7,12], with HPV being strongly prognostic
for survival in OPSCC [9]. Human papillomavirus sta-
tus also differs substantially with geographical loca-
tion, with HPV prevalence in OPSCCs found to be higher
in North America and Asia than in Europe [13]. However,
this may be confounded by testing only for the HPV types
that are most common in North America, and therefore
other high-risk types of HPV may be more prevalent
elsewhere in the world.
p16 is a tumour suppressor and cell-cycle regulator
that is upregulated in HPV-positive OPSCC and often
lost in HPV-negative OPSCC. In OPSCC, p16 expression
is well established as a surrogate marker of HPV infection
and is also associated with prognosis [14,15]. Indeed,
patients with p16-positive oropharyngeal cancer have
significantly improved failure-free survival and overallsurvival versus patients with p16-negative oropharyngeal
cancer (failure-free survival hazard ratio = 0.28, P < 0.001
and overall survival hazard ratio = 0.31, P = 0.002)
[16]. Recent evidence also suggests that patients with
p16-positive OPSCC have improved progression-free
survival and overall survival compared with p16-positive
patients with non-OPSCC, but patients with p16-negative
OPSCC and non-OPSCC have similar outcomes [14].
Overall survival in patients with high-risk locoregionally
advanced OPSCC is low; in the Radiation Therapy
Oncology Group 0129 trial reported by Ang et al. [9],
these patients demonstrated a 3-year overall survival
rate of 46.2% following concurrent chemoradiotherapy,
compared with 93% in a low-risk group and 70.8% in
an intermediate-risk group. In a study reported by
Broglie et al. in 2012 [11], similar figures were described:
3-year survival rates of 65% in a high-risk group, 88% in a
low-risk group and 77% in an intermediate-risk group. In
the Radiation Therapy Oncology Group 0129 study,
patients with HPV-negative OPSCC had a significantly
worse 3-year survival rate (57.1% versus 82.4%; P < 0.001),
a worse 3-year progression-free survival rate (43.4% versus
73.7%; P < 0.001), significantly more locoregional relapses
(35.1% versus 13.6%; P < 0.001) and significantly more
second primary tumours (14.6% versus 5.9%; P = 0.02)
versus patients with HPV-positive OPSCC. Therefore,
because of the available data on the prognostic factors in
OPSCC, both patients with p16-negative locoregionally
advanced OPSCC and patients with non-OPSCC locore-
gionally advanced disease were considered to have high-risk
locoregionally advanced HNSCC.
Non-targeted treatment of locoregionally advanced HNSCC
Following diagnosis of primary locoregionally advanced
HNSCC, standard treatment options are concurrent
chemoradiotherapy, radiotherapy alone, induction chemo-
therapy followed by radiotherapy, or concurrent chemora-
diotherapy [8], with cisplatin being the most common
chemotherapy used in combination with radiotherapy [2].
In a meta-analysis by Pignon et al. [17], an absolute overall
survival benefit of 6.5% at 5 years was associated with
concomitant chemoradiotherapy; the benefit was only 1%
for adjuvant chemotherapy and 2% for neoadjuvant chemo-
therapy in patients previously untreated for locoregionally
advanced disease. Although there is a genuine improvement
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the overall survival benefit is still low. Furthermore,
as mentioned previously, the 3-year overall survival
observed for concurrent chemoradiotherapy in patients
with untreated HPV-negative oropharyngeal cancer is only
57% and the risk of locoregional relapse is 35% [9].
The use of chemotherapy after locoregional treatment
has been studied in only a limited number of randomized
trials in HNSCC. Early studies examining the impact of
chemotherapy in the maintenance setting demonstrated
modest, but minimal, benefits, and these did not translate
into a survival benefit overall [18-20]. A significant survival
advantage was seen only in a subgroup of patients with
N2 disease in a subset analysis of the Head and Neck
Contracts Programme, suggesting that maintenance
chemotherapy may only be appropriate for patients with
advanced disease [18]. A meta-analysis of 23 chemotherapy
trials evaluating the timing of chemotherapy (including 10
trials with maintenance treatment) suggested that cancer
mortality was only influenced by both synchronous
and maintenance chemotherapy [21]. However, most
of the trials in this meta-analysis were small, and a
direct comparison of maintenance versus no maintenance
was not conducted. Toxicities in these combined modality
treatments were also substantial and dose-limiting.
Therefore, despite signals of some survival benefit, the use
of cytotoxic chemotherapy after locoregional treatment
has not gained acceptance within clinical practice. With
the more recent advent of targeted therapies (in particular
those that can be orally administered), re-examination of
the question of continuing systemic therapy beyond the
completion of chemoradiation is warranted.
Targeted treatment approaches
Epidermal growth factor receptor (EGFR; ErbB1) is
expressed in over 90% of HNSCCs [22], with high levels
of EGFR protein expression being associated with de-
creased survival, resistance to radiotherapy, locoregional
treatment failure and high rates of distant metastases [23].
A 2011 study showed that patients with HNSCC and high
EGFR protein expression display inferior 5-year overall
survival rates, compared with patients with HNSCC
and low EGFR protein expression (P = 0.029) [24].
Cetuximab, an EGFR-targeting monoclonal antibody,
is the only targeted treatment approved in the USA,
Japan and Europe for HNSCC, where it is approved
in combination with radiotherapy for the treatment of
locoregionally advanced disease [25,26]. In the same
regions, cetuximab is also approved for the first-line treat-
ment of recurrent or metastatic HNSCC in combination
with platinum-based chemotherapy. The US label also
indicates cetuximab monotherapy for the second-line treat-
ment of recurrent or metastatic HNSCC following failure
of platinum-based chemotherapy [25,26].In patients with untreated locoregionally advanced
HNSCC, cetuximab plus radiotherapy compared with
radiotherapy alone showed a statistically significant im-
provement in the primary endpoint of locoregional control
(median, 24.4 months versus 14.9 months; P = 0.005), as
well as the secondary endpoints of overall survival (median,
49 months versus 29.3 months; P = 0.03) and progression-
free survival (median, 17 months versus 12 months;
P = 0.006) [27]. Cetuximab also impacts survival in the re-
current or metastatic setting. The proof-of-principle study
conducted by the Eastern Cooperative Oncology Group
(ECOG) compared cisplatin plus cetuximab versus cis-
platin plus placebo in patients with measurable or evalu-
able recurrent or metastatic HNSCC; this demonstrated a
significant improvement in objective response rate (26%
versus 10%), but was underpowered for progression-free
survival and overall survival [28]. A larger (n = 442) phase
III study, in which cetuximab plus platinum/5-fluorouracil
was compared with platinum/5-fluorouracil alone, did
show an impact on survival, demonstrating an improve-
ment from 7.4 months for the control arm to a median of
10.1 months for the cetuximab arm [29]. However, median
overall survival still remains unsatisfactory in the recur-
rent or metastatic setting and there is an urgent need for
further improvement.
Extensive cross-talk between all ErbB-dependent sig-
nalling pathways in HNSCC, as well as the numerous
molecular and genetic aberrations present, contribute to
the development of cetuximab resistance [30]. Acquired
resistance to cetuximab has been linked to dysregulation
of EGFR internalization or degradation, EGFR-dependent
activation of human epidermal growth factor receptor 2
(HER2; ErbB2) and ErbB3, and increased signalling of
alternative receptor tyrosine kinases, such as cMET [31].
To overcome treatment resistance, new investigational
therapies target more than one member of the ErbB family
of receptors simultaneously, reversibly or irreversibly [23].
Lapatinib, a dual reversible EGFR/HER2 small-molecule
tyrosine kinase inhibitor, is currently being assessed in the
maintenance setting versus placebo (both in combination
with chemoradiotherapy) in a phase III study in patients
with high-risk HNSCC who have undergone resection
[32]. Results are expected in mid-2014. Another strategy
is irreversible blockade of all members of the ErbB family,
which might compromise all ErbB-mediated signalling
pathways and cause sustained blockade of ErbB receptor
dimers. This might lead to suppression of tumour growth
and, it is expected, improved efficacy. Given the central
role of the ErbB family in the tumourigenesis of HNSCC,
this is an attractive target for treatment in the adjuvant
setting. This may be especially useful when an aggressive
multimodal treatment approach is needed to combat fur-
ther tumour growth and prevent the development of
metastatic disease.
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Afatinib is an oral, irreversible ErbB family blocker that
completely and irreversibly blocks signalling by EGFR,
HER2 and ErbB4. It also blocks transphosphorylation of
ErbB3 [33,34]. Afatinib is approved in the major ICH
(International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for
Human Use) regions of the USA, EU and Japan for
the treatment of patients with non-small cell lung
cancer harbouring distinct EGFR activating mutations
[35-37]. Afatinib is also undergoing development as a
therapy for several other ErbB-driven cancers. Approval
was based on findings from the pivotal phase III LUX-Lung
3 study, which demonstrated a median progression-free
survival of 11.1 months in patients treated with afatinib
versus 6.9 months in patients treated with chemotherapy
(P < 0.001) in the first-line EGFR mutation-positive setting
[38]. In more recent analyses, an overall survival benefit
with afatinib versus chemotherapy was also observed
in patients with non-small cell lung cancer harbouring the
EGFR Del19 mutation [39].
Preclinical activity of afatinib in HNSCC has been
observed in human HNSCC FaDu mouse models [40],
whilst in-vitro combination experiments demonstrated
additive activity of afatinib when combined with standard
chemotherapy [41]. Furthermore, proof of concept for
afatinib in HNSCC has been demonstrated in a phase II
crossover study of afatinib versus cetuximab, in which
comparable activity of both agents was observed in
patients with recurrent or metastatic HNSCC for whom
platinum-based chemotherapy had failed. Objective
response rates in stage 1 of the study were 8.1% in
the afatinib group and 9.7% in the cetuximab group
(independent central review) [42]. In stage 2 of the study,
after crossover had occurred, the disease control rate
(including complete response, partial response and stable
disease) was 33% in afatinib-treated patients versus 19% in
cetuximab-treated patients [42]. Furthermore, in stage 2
of the study, the progression-free survival time was 9.3
weeks for afatinib-treated patients (following cetuximab in
stage 1 of the study) and 5.7 weeks in cetuximab-treated
patients (following afatinib in stage 1 of the study).
Although stage 2 of the study was not powered to detect a
significant difference in progression-free survival between
treatment groups, these data suggest that sequential
therapy with EGFR- or ErbB family-targeted agents
might have clinical benefit in patients with recurrent
or metastatic HNSCC.
Gastrointestinal and dermatological side effects are
common in patients receiving EGFR tyrosine kinase
inhibitors, and have a large impact on patients’ quality of
life. Afatinib has a manageable tolerability profile in
clinical trials, with toxicity dominated particularly by
gastrointestinal and dermatological side effects. Recentpooled data analyses suggest that adverse events associated
with afatinib can be effectively managed in patients with
solid tumours [43,44].
The dosage for afatinib was initially established during
monotherapy trials, with a maximum tolerated daily dose
of either 40 or 50 mg [45,46]. LUX-Lung 2 evaluated
50 mg/day afatinib in patients with EGFR mutation-positive
non-small cell lung cancer who had received ≤1 prior
chemotherapy regimen. This dose was reduced to 40
mg/day following a protocol amendment to improve afati-
nib’s tolerability profile [47]. No difference in activity be-
tween these doses was observed in patients in LUX-Lung 2
and thus 40 mg/day afatinib was selected as the starting
dose in the LUX-Lung 3 and 6 studies [38,48,49]. In the
HNSCC proof-of-concept phase II trial, the starting
dose of 50 mg/day afatinib was not as well tolerated
as 40 mg/day afatinib. In stage 1 of this trial, 18 of 61
(29.5%) afatinib-treated patients had their dose reduced
from 50 to 40 mg/day in response to an adverse event,
with the most frequently reported adverse events that led
to dose reductions being diarrhoea and rash. In stage
2 of the trial, 11 of 36 (30.6%) afatinib-treated patients
experienced dose reductions to 40 mg/day following an
adverse event; diarrhoea and rash were again the most
common reason for dose reduction. Given the projected
long duration of therapy in a group of patients who are
likely to have low-grade persisting toxicities of chemoradio-
therapy, an initial dose of 40 mg/day afatinib is utilized in
LUX-Head & Neck 2, with individual dose modifications.
The LUX-Head & Neck 2 trial (NCT01345669) investi-
gates the efficacy and tolerability of afatinib compared with
placebo when given as adjuvant therapy after chemoradio-
therapy, in patients with primary unresected HNSCC prior
to chemoradiotherapy and no evidence of disease (with or
without salvage tumour resection or neck dissection) post-
chemoradiotherapy. The hypothesis being tested is that
prolonged, irreversible, small-molecule inhibitor-mediated
ErbB family blockade will improve disease-free survival
outcomes. The study aims to select patients with unfavour-
able prognosis according to disease stage, tumour site and
smoking status or history.Methods/Design
Objectives
The primary objective of this study is to evaluate the
superiority of afatinib as adjuvant therapy versus placebo
in terms of disease-free survival (primary endpoint)
following chemoradiotherapy in patients with primary
unresected locoregionally advanced (stage III, IVa or IVb)
HNSCC. Secondary endpoints include the disease-free
survival rate at 2 years, overall survival rate, health-related
quality of life and safety. Voluntary biomarker assessments
were also conducted.
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The LUX-Head & Neck 2 trial is a randomized, multicentre,
double-blind, placebo-controlled, phase III trial. Patients will
undergo magnetic resonance imaging, positron emission
tomography or computed tomography approximately 8 to
12 weeks after completion of chemoradiotherapy and, if
there is no evidence of disease, patients will be randomized
no later than 24 weeks post-chemoradiotherapy to either
afatinib or placebo in the ratio 2:1. Randomization
will be conducted centrally with a validated random
number-generating system at Boehringer Ingelheim,
verified by a trial-independent statistician, and implemented
via an interactive internet and voice-response system.
Access to the randomization code will be supervised
by the clinical trial support group; those directly involved
in the conduct and analysis of the trial will not have access
to the randomization schedule prior to database lock.
Stratification will be based on patients’ nodal status (N0 to
N2a versus N2b to N3, based on the TNM Staging Classi-
fication for Head and Neck Cancers) [8] and ECOG per-
formance status (0 versus 1) at randomization. Eligible
patients will receive, as adjuvant therapy, either continu-
ous oral once-daily afatinib at a starting dose of 40 mg or
placebo, which will be administered for 18 months or until
disease recurrence or unacceptable adverse events occur.
The dose of afatinib will be escalated to 50 mg in patients
with no or minimal drug-related adverse events or
will be reduced to 40 mg (if first escalated to 50 mg),
30 mg or 20 mg in patients experiencing drug-related
adverse events (Figure 1).
This trial is expected to randomize 669 patients to
treatment worldwide (446 in the afatinib arm and 223 in
the placebo arm) and will be carried out in compliance
with the protocol, and in accordance with the principles
laid down in the Declaration of Helsinki, the International
Conference on Harmonisation Guideline for Good Clin-
ical Practice and applicable regional-specific regulatoryFigure 1 Trial design.requirements. The study protocol has been reviewed by
an independent ethics committees (please see Additional
file 1 for details of all approving committees), according to
national and international regulations, and written in-
formed consent will be obtained from each patient before
any study-specific screening assessments are performed.
An independent data monitoring committee will oversee
the trial and will advise on the further conduct of the trial
based on ongoing evaluation of efficacy and safety data.
Patients
Eligible patients must be ≥18 years of age, have an
ECOG performance status of 0 or 1 and have histologi-
cally or cytologically confirmed locoregionally advanced
HNSCC at the time of randomization (stage III, IVa or
IVb squamous cell carcinoma of the oral cavity, orophar-
ynx or hypopharynx, or stage IVa or IVb squamous cell
carcinoma of the larynx). Patients are required to have
unresected disease prior to chemoradiotherapy and an
unfavourable risk of recurrence. Patients can have unre-
sected disease for the following reasons: (1) they may
have technically unresectable disease owing to tumour
fixation, or invasion to either base of the skull, cervical
vertebrae, nasopharynx or fixed lymph nodes; (2) there
may be low surgical curability (T3 or T4, N2 or N3 ex-
cluding T1N2, based on the TNM Staging Classification
for Head and Neck Cancers) [8]; or (3) patients may be
treated for organ preservation. As HPV status will not
be determined for eligibility in this study, unfavourable
risk is defined as non-oropharynx primary site or orophar-
ynx cancer in heavy smokers (>10 pack-years). Patients
must also have completed prior definitive platinum-based
chemoradiotherapy by no longer than 24 weeks prior to
randomization (at least two cycles of cisplatin at a mini-
mum cumulative dose of 200 mg/m2 or carboplatin at a
minimum cumulative area under the concentration-time
curve of 9; radiotherapy of minimum 66 Gy in 33 fractions
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have chemoradiotherapy-induced adverse events classified
as less than or equal to grade 2 using the Common
Terminology Criteria for Adverse Events. Patients are re-
quired to have no evidence of disease after chemoradiother-
apy (that is, no residual tumour after chemoradiotherapy,
or no residual tumour after chemoradiotherapy followed by
R0 tumour resection, or no evidence of nodal disease after
chemoradiotherapy followed by neck dissection). Patients
must also have adequate bone marrow, liver and kidney
function. The main exclusion criteria are prior treatment
with EGFR-targeted small molecules, EGFR-targeted anti-
bodies or any investigational agents for HNSCC, patients
with a smoking history of ≤10 pack-years and with primary
tumour site of base of tongue or tonsil, and primary cancer
of nasopharynx, sinuses or salivary glands.Efficacy assessments
Disease-free survival, the primary endpoint measure, is
defined as the time from randomization until docu-
mented tumour recurrence or second primary tumour
or death of any cause, whichever occurs first. The defin-
ition of recurrence or second primary tumour is the ap-
pearance of any new lesions without any evident benign
aetiology, assessed by imaging of the head and neck and
chest by the investigator and an independent central re-
view. The primary analysis will be based on the investi-
gator’s assessment. Tumour recurrence will be further
classified into subtypes of local, regional or distant re-
currence. Disease-free survival rate at 2 years, the key
secondary endpoint, will be calculated in each group
using the Kaplan-Meier method. Overall survival is de-
fined as time from the date of randomization until
death.Safety assessments
The incidence and intensity of adverse events will be
evaluated according to the National Cancer Institute
Common Terminology Criteria for Adverse Events ver-
sion 3.0. All adverse events, serious and non-serious, oc-
curring during the course of the trial (that is, from
randomization until 28 days after end of treatment), re-
gardless of relatedness to study medication, will be col-
lected, documented and reported by the investigator.
Serious and non-serious adverse events occurring later
than 28 days after the last administration of study medi-
cation will only be reported if they are considered rele-
vant by the investigator. All adverse events, including
those persisting after the end of the study medication,
must be followed up until they have resolved or have
been sufficiently characterized. Safety endpoints are the
overall incidence and intensity of adverse events, gastro-
intestinal events (vomiting, nausea and diarrhoea), skinreactions (rash, acne) and change from baseline in all la-
boratory tests.
Health-related quality of life assessment
Health-related quality of life will be assessed using
the following patient-reported outcome measures:
European Organisation for Research and Treatment of
Cancer Quality of Life Questionnaire (QLQ-C30); European
Organisation for Research and Treatment of Cancer Quality
of Life Head and Neck cancer module (QLQ-H&N35);
and EQ-5D health status questionnaire. Questionnaires will
be completed at randomization and at each tumour assess-
ment time point until disease recurrence. Questionnaires
will be filled in by the patients at the clinic before any clin-
ical assessment and treatment, and before provision of any
new information about their disease status.
Biomarker assessment
Participation in the biomarker analysis is voluntary and
is not a prerequisite for participation in the trial. Separ-
ate informed consent must be provided by patients for
this part of the study, in accordance with local ethical
and regulatory requirements. Biomarker analyses will be
performed using archival tumour tissue; fresh tumour
biopsies are not possible as there is no residual disease
in participating patients. Exploratory biomarkers to be
assessed are p16 status, ErbB ligands, ErbB receptor ex-
pression, EGFR mutational or activation status and ErbB
downstream signalling markers.
Statistical analyses
This trial is powered to detect a prolonged median
disease-free survival of 6.2 months with afatinib over an
assumed disease-free survival of 15.8 months in the pla-
cebo arm [8]. A total of 669 patients randomized 2:1 to
afatinib and placebo is required to detect a difference in
disease-free survival (with a hazard ratio of 0.72) at a
power of 90%, with a one-sided type-I error of α = 0.025.
Disease-free survival will be analyzed using the strati-
fied log-rank test with nodal status (N0 to N2a versus
N2b to N3) and ECOG performance status (0 versus 1)
being the stratification factors. The Kaplan-Meier method
will be used to estimate the 25th percentile, median and
75th percentile disease-free survival for each treatment
group and the stratified Cox proportional hazards model
will be used to derive the hazard ratio between the two
treatment groups. The difference in the disease-free sur-
vival rate at 2 years between afatinib and placebo (dKM)
will be calculated as the difference between the two
Kaplan-Meier estimates. Overall survival will be ana-
lyzed using the stratified log-rank test, the Kaplan-
Meier method and the stratified Cox proportional hazards
model, in the same manner as for disease-free survival.
Figure 2 Trial countries.
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A detailed account of the LUX-Head & Neck 2 trial has
been provided here to increase awareness of this study
and provide a detailed rationale for assessment of afatinib
in the adjuvant setting. It is important that patients with
intermediate-to-high-risk primary unresected locoregion-
ally advanced HNSCC are informed of the risk of recur-
rence or distant metastases following initial treatment.
With the limited treatment options following chemoradio-
therapy, sharing information on clinical trials of novel
treatment options with patients is critical to provide them
with the opportunity to participate in these studies.
The LUX-Head & Neck 2 trial will demonstrate
whether afatinib reduces the risk of recurrent or meta-
static disease following adjuvant treatment in patients
with intermediate-to-high-risk primary unresected HNSCC,
and will provide further knowledge on the treatment of
this patient population. This is one of two phase III
studies of afatinib in HNSCC; LUX-Head & Neck 1
(NCT01345682) is assessing afatinib versus methotrex-
ate in patients with recurrent or metastatic HNSCC
who have progressed with platinum-based therapy [50].
The primary endpoint for this trial has been completed
and results from the study were presented at the European
Society for Medical Oncology 2014 congress [51].
Novel activity of afatinib has been shown in preclinical
models of head and neck cancer [40,41] and comparableactivity has been seen versus cetuximab in the proof-of-
concept phase II trial [42]. Given these data and the
clinical efficacy of afatinib in non-small cell lung cancer
[38], similar data may be reflected here in the phase III
LUX-Head & Neck 2 trial.
Trial status
The trial was initiated in October 2011 and is currently
recruiting patients in Argentina, Australia, Austria, Belgium,
Brazil, Canada, Chile, the Czech Republic, Denmark, Finland,
France, Germany, Greece, Hungary, India, Israel, Italy, Japan,
Mexico, Portugal, Russia, Spain, Sweden, Switzerland, the
Netherlands, the UK and the USA (Figure 2). Other partici-
pating countries are Egypt, Poland and Ukraine.Additional file
Additional file 1: List of approving institutional review boards and
independent ethics committees.
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